The Clinical Oncology Next Generation Sequencing (NGS) Market is expected to register a CAGR of 16% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Clinical Oncology Next Generation Sequencing (NGS) Market report covers segmental analysis by Technology (Whole Exome Sequencing, Whole Genome Sequencing, Targeted Sequencing and Resequencing); Workflow (NGS Data Analysis, NGS Pre-Sequencing, NGS Sequencing); Application (Companion Diagnostics, Screening, Other Applications); End User (Hospitals and Clinics, Laboratories), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries
Purpose of the ReportThe report Clinical Oncology Next Generation Sequencing (NGS) Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation
Technology- Whole Exome Sequencing
- Whole Genome Sequencing
- Targeted Sequencing and Resequencing
- NGS Data Analysis
- NGS Pre-Sequencing
- NGS Sequencing
- Companion Diagnostics
- Screening
- Other Applications
- Hospitals and Clinics
- Laboratories
Strategic Insights
Clinical Oncology Next Generation Sequencing (NGS) Market Growth Drivers- Increase in Cancer Prevalence: The global rise in cancer cases is one of the most significant factors influencing the growth of the Clinical Oncology NGS market. As cancer incidence continues to increase, there is a growing need for advanced diagnostic tools like NGS that can provide insights into the genetic makeup of tumors. NGS technologies help identify specific genetic mutations that can influence cancer progression, making them essential for detecting cancers at early stages and monitoring treatment efficacy. This rising demand for more accurate and non-invasive diagnostic solutions boosts the growth of the NGS market in oncology.
- Growing Focus on Liquid Biopsy: Liquid biopsy, a non-invasive diagnostic method that utilizes blood samples to detect genetic alterations and mutations, is gaining traction in the clinical oncology NGS market. With liquid biopsy, NGS can be used to analyze circulating tumor DNA (ctDNA), offering an easier, quicker, and less invasive alternative to traditional tissue biopsies. The rise of liquid biopsy technologies is revolutionizing cancer detection, monitoring, and recurrence tracking, thus contributing to the expanding use of NGS in clinical oncology.
- Improved Awareness and Adoption by Healthcare Providers: As clinical oncologists and healthcare providers become more aware of the capabilities and benefits of NGS, the adoption of these technologies has increased significantly. Many healthcare systems are integrating NGS into standard oncology care, recognizing its ability to provide critical insights into the genetic landscape of tumors. The increasing availability of NGS-based diagnostic tools in clinical settings has led to wider acceptance of genomic testing as a routine part of cancer care, fueling the Clinical Oncology NGS market's expansion.
- Expansion of NGS-based Companion Diagnostics: NGS is increasingly being used to identify biomarkers that can predict patient responses to targeted therapies, creating opportunities for companion diagnostics. In the future, Clinical Oncology NGS will play an integral role in the development and widespread adoption of companion diagnostic tests, which pair specific drugs with genetic profiles to optimize treatment outcomes. As the number of targeted cancer therapies expands, the demand for NGS-based companion diagnostics will grow, helping oncologists make more informed decisions about personalized treatment regimens.
- Broader Use of Whole Genome Sequencing (WGS) in Clinical Oncology: Whole genome sequencing (WGS), which involves analyzing the entire genome, is expected to become more widely adopted in clinical oncology. As WGS technology becomes more affordable and accessible, it will offer a comprehensive view of a patient's genetic makeup, enabling the detection of rare mutations and complex genomic alterations. This will further enhance the ability to tailor personalized treatment strategies based on the individual characteristics of the tumor, allowing oncologists to provide more precise and effective cancer care.
- Enhanced Focus on Multi-Omics Approaches: The future of Clinical Oncology NGS will see a growing emphasis on multi-omics approaches, where genomics, proteomics, transcriptomics, and other omics data are integrated to create a more complete picture of cancer biology. By combining data from different omics layers, NGS technologies can provide deeper insights into the molecular mechanisms underlying cancer, improving early detection, prognosis assessment, and treatment selection. This trend will enable more holistic and precise approaches to cancer care, moving beyond genomics alone to a broader systems biology perspective.
- Next-Generation Cancer Screening Programs: As the sensitivity and affordability of Clinical Oncology NGS technologies improve, they will increasingly be used in large-scale cancer screening programs. NGS platforms, particularly through liquid biopsy, will play a key role in early cancer detection, particularly in asymptomatic individuals or those at high risk. These advancements will lead to broader population screening initiatives, enabling earlier and more accurate detection of various cancer types, ultimately improving survival rates and reducing healthcare costs associated with late-stage cancer treatments.
- Increased Regulatory Approvals and Reimbursement for NGS Tests: In the future, more regulatory agencies and insurance providers are expected to approve and reimburse NGS-based cancer tests, expanding access to these advanced diagnostic tools. As the clinical utility and cost-effectiveness of Clinical Oncology NGS continue to be demonstrated in oncology trials and clinical settings, healthcare reimbursement for NGS-based diagnostics will become more widespread. This trend will remove some of the financial barriers for patients and healthcare systems, making NGS testing more accessible across global markets.
- Rise of Pan-Cancer NGS Panels: The development and adoption of pan-cancer NGS panels that can detect a wide range of genetic mutations across different cancer types is another key future trend in the Clinical Oncology NGS market. These panels offer the advantage of being able to test for multiple genetic alterations simultaneously, regardless of the cancer type. This versatility makes pan-cancer panels particularly useful for identifying novel biomarkers, monitoring minimal residual disease, and selecting targeted therapies. The growth of pan-cancer testing will enhance the efficiency of cancer diagnostics and treatment decision-making, driving further demand for NGS solutions.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Clinical Oncology Next Generation Sequencing (NGS) Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Clinical Oncology Next Generation Sequencing (NGS) Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Clinical Oncology Next Generation Sequencing (NGS) Market is expected to register a CAGR of 16% from 2025-2031.
The major factors impacting the Clinical Oncology Next Generation Sequencing (NGS) Market are: Increase in Cancer Prevalence, Growing Focus on Liquid Biopsy and Improved Awareness and Adoption by Healthcare Providers
Key future trends in this market are - Expansion of NGS-based Companion Diagnostics, Broader Use of Whole Genome Sequencing (WGS) in Clinical Oncology and Enhanced Focus on Multi-Omics Approaches
Key companies of this market are: Agilent Technologies, Inc., Caris Life Sciences, F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, PerkinElmer Inc, QIAGEN, Thermo Fisher Scientific Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market - By Technology
1.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market - By Workflow
1.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market - By Application
1.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market - By End User
1.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - GLOBAL MARKET ANALYSIS
6.1. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET OVERVIEW
6.2. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. WHOLE EXOME SEQUENCING
7.3.1. Overview
7.3.2. Whole Exome Sequencing Market Forecast and Analysis
7.4. WHOLE GENOME SEQUENCING
7.4.1. Overview
7.4.2. Whole Genome Sequencing Market Forecast and Analysis
7.5. TARGETED SEQUENCING AND RESEQUENCING
7.5.1. Overview
7.5.2. Targeted Sequencing and Resequencing Market Forecast and Analysis
8. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - WORKFLOW
8.1. OVERVIEW
8.2. WORKFLOW MARKET FORECASTS AND ANALYSIS
8.3. NGS DATA ANALYSIS
8.3.1. Overview
8.3.2. NGS Data Analysis Market Forecast and Analysis
8.4. NGS PRE-SEQUENCING
8.4.1. Overview
8.4.2. NGS Pre-Sequencing Market Forecast and Analysis
8.5. NGS SEQUENCING
8.5.1. Overview
8.5.2. NGS Sequencing Market Forecast and Analysis
9. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. COMPANION DIAGNOSTICS
9.3.1. Overview
9.3.2. Companion Diagnostics Market Forecast and Analysis
9.4. SCREENING
9.4.1. Overview
9.4.2. Screening Market Forecast and Analysis
9.4.3. Inherited Cancer Market
9.4.3.1. Overview
9.4.3.2. Inherited Cancer Market Forecast and Analysis
9.4.4. Sporadic Cancer Market
9.4.4.1. Overview
9.4.4.2. Sporadic Cancer Market Forecast and Analysis
9.5. OTHER APPLICATIONS
9.5.1. Overview
9.5.2. Other Applications Market Forecast and Analysis
10. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. LABORATORIES
10.4.1. Overview
10.4.2. Laboratories Market Forecast and Analysis
11. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.1.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.1.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.1.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.1.5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.1.6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.1.7 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.1.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.1.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.1.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.1.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.2.1 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.2.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.2.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.2.4 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.3.1 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.3.2 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.3.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2. EUROPE
11.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.2.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.2.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.2.6 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.2.7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.1.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.1.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.1.3 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.1.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.2 France Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.2.1 France Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.2.2 France Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.2.3 France Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.2.4 France Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.3.1 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.3.2 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.3.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.3.4 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.4.1 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.4.2 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.4.3 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.4.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.5 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.5.1 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.5.2 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.5.3 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.5.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.6 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.6.1 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.6.2 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.6.3 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.6.4 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.3.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.3.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.1.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.1.2 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.1.3 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.1.4 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.2.1 China Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.2.2 China Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.2.3 China Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.2.4 China Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.3 India Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.3.1 India Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.3.2 India Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.3.3 India Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.3.4 India Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.4.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.4.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.4.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.4.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.5 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.5.1 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.5.2 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.5.3 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.5.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.6 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.6.1 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.6.2 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.6.3 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.6.4 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.4.2 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.4.3 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.4.4 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.4.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.1.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.1.2 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.1.3 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.1.4 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.2.1 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.2.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.2.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.2.4 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.3.1 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.3.2 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.3.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.3.4 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.4.1 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.4.2 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.4.3 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.4.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.5.2 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.5.3 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.5.4 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.5.5 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.5.6 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.1.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.1.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.1.3 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.1.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.2.1 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.2.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.2.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.2.4 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.3.1 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.3.2 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.3.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.3.4 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CARIS LIFE SCIENCES
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. FOUNDATION MEDICINE, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ILLUMINA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYRIAD GENETICS, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OXFORD NANOPORE TECHNOLOGIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PERKINELMER INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERMO FISHER SCIENTIFIC INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
4. FOUNDATION MEDICINE, INC.
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. PerkinElmer Inc
9. QIAGEN
10. Thermo Fisher Scientific Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For